# CDKN2A (p16INK4a / p14ARF): Cell Cycle Kinase Inhibition, ARF-MDM2 Axis, and Melanoma Risk


## Key Takeaways

- The **CDKN2A locus** encodes two distinct tumor suppressors, **p16INK4a** and **p14ARF**, via alternative promoters and reading frames, crucial for cell cycle control and p53 stabilization, respectively.
- **Germline mutations** in CDKN2A confer a significantly elevated risk for cutaneous malignant melanoma and pancreatic adenocarcinoma, with recurrent missense mutations often disrupting p16INK4a's ankyrin repeats and CDK4/6 binding.
- **Somatic alterations**, including homozygous deletions at 9p21.3 and promoter hypermethylation, frequently inactivate CDKN2A across various sporadic cancers, creating dependencies exploited by targeted therapies.
- **p16INK4a** enforces the G1/S checkpoint by inhibiting CDK4/6, while **p14ARF** stabilizes p53 by sequestering MDM2, acting as a critical sensor of oncogenic stress.
- **CDK4/6 inhibitors** (e.g., palbociclib, ribociclib, abemaciclib) are therapeutically effective in cancers with CDKN2A loss or RB1 retention, while **MDM2 inhibitors** are being developed for p53-wild-type tumors lacking p14ARF.

---

## Executive Summary & Key Metadata

The **CDKN2A** locus (Cyclin-Dependent Kinase Inhibitor 2A) is among the most frequently altered tumor suppressor genes in human cancer. Its unique genomic architecture encodes two structurally and functionally distinct proteins—**p16INK4a** and **p14ARF**—through the use of alternative reading frames and independent promoters. p16INK4a functions as a negative regulator of the cell cycle by inhibiting cyclin-dependent kinases 4 and 6 (CDK4/6), thereby enforcing the G1/S checkpoint. p14ARF operates within the nucleolus to stabilize p53 by sequestering MDM2, thus linking oncogenic stress to apoptosis and senescence. Germline mutations in CDKN2A confer a markedly elevated risk of cutaneous malignant melanoma and pancreatic adenocarcinoma. Somatic alterations—including promoter methylation, intragenic deletions, and point mutations—are observed across a broad spectrum of sporadic cancers.

| **Attribute** | **Value** |
|---|---|
| HGNC Symbol | CDKN2A |
| UniProt Accession | P42771 (p16INK4a); Q8N726 (p14ARF, human) |
| Representative PDB ID | 1BI7 (p16INK4a, NMR structure) |
| Chromosomal Locus | 9p21.3 (GRCh38: chr9:21,967,752–21,995,324) |
| Primary Molecular Function | Cyclin-dependent kinase inhibitor (p16INK4a); p53 stabilizer via MDM2 sequestration (p14ARF) |
| Disease & Pathology Associations | Familial atypical multiple mole melanoma (FAMMM), pancreatic cancer, multiple sporadic cancers |
| Gene Size | ~27.5 kb |
| Number of Transcripts | ≥5 (major: p16INK4a, p14ARF, p12) |
| Subcellular Localization | p16INK4a: nuclear/cytoplasmic; p14ARF: nucleolar |

---

## 1. Genomic Locus, Chromosomal Organization & Isoforms

### 1.1 Chromosomal Context

CDKN2A resides on the **short arm of chromosome 9** at band **9p21.3**, a genomic region notorious for its density of tumor suppressor genes and its susceptibility to large-scale deletions in cancer. The locus spans approximately **27.5 kilobases** (kb) on the forward strand of GRCh38 (chr9:21,967,752–21,995,324). The region is gene-dense: immediately adjacent to CDKN2A lies **CDKN2B** (encoding p15INK4b), located ~25 kb centromeric, and **MTAP** (methylthioadenosine phosphorylase) lies telomeric. The close proximity of CDKN2A and CDKN2B means that heterozygous or homozygous deletions frequently encompass both genes, a common event in glioblastoma, mesothelioma, and acute lymphoblastic leukemia.

### 1.2 Promoter Architecture and Regulatory Elements

The CDKN2A locus is controlled by **two independent promoters** separated by approximately 13 kb. The upstream promoter (proximal to the p16INK4a first exon, Exon 1α) drives transcription of the p16INK4a transcript. The downstream promoter, located within intron 2, drives transcription of the p14ARF transcript beginning at Exon 1β. This arrangement permits independent transcriptional regulation of the two proteins, a feature critical for their distinct physiological roles.

**Promoter 1α (p16INK4a):** Contains multiple binding sites for transcription factors including **SP1**, **E2F1**, and **AP2**. The promoter is subject to epigenetic silencing via **CpG island hypermethylation**—a frequent event in colorectal, lung, and breast cancers. The p16INK4a promoter is also positively regulated by **ETS1/ETS2** transcription factors, which bind to a conserved ETS-binding motif. Conversely, the polycomb repressive complex 2 (PRC2) maintains H3K27me3 marks at this promoter in proliferating cells, and its derepression is a hallmark of cellular senescence.

**Promoter 1β (p14ARF):** This promoter is regulated by **E2F1** and **Myc**—both of which are activated by proliferative signals. Notably, p14ARF transcription is induced by oncogenic stress (e.g., aberrant Myc or Ras activation) as a failsafe mechanism. The promoter also contains a **p53-responsive element**, creating a negative feedback loop: p53 activation induces p14ARF, which stabilizes p53, but sustained p53 activity eventually represses p14ARF transcription.

### 1.3 Alternative Splicing and Isoform Diversity

The CDKN2A locus produces multiple transcripts through alternative splicing and the use of alternative first exons:

1. **p16INK4a (156 amino acids):** Composed of Exons 1α, 2, and 3. The open reading frame (ORF) spans all three exons, with Exon 3 contributing the C-terminal 11 amino acids. This is the canonical CDK4/6 inhibitor.
2. **p14ARF (132 amino acids in humans):** Composed of Exons 1β, 2, and 3. The ORF begins in Exon 1β and continues into Exon 2 but in the **+1 reading frame** relative to p16INK4a. Thus, Exon 2 encodes entirely different amino acid sequences for the two proteins. p14ARF lacks the ankyrin repeat domain of p16INK4a.
3. **p12:** A shorter variant of p14ARF produced by alternative splicing that skips Exon 2, resulting in a 75-amino-acid protein. Its function is less well characterized but may modulate ARF activity.
4. **p16INK4a-γ:** A recently described isoform with altered C-terminal sequences, implicated in some cancers.

The **shared Exon 2** is a mutational hotspot for both proteins. A single nucleotide change in Exon 2 can alter the amino acid sequence of p16INK4a, p14ARF, or both, depending on the reading frame and codon position. This "dual-coding" feature complicates genotype–phenotype correlations in familial melanoma kindreds.

### 1.4 Evolutionary Conservation

The dual-coding arrangement of CDKN2A is conserved in mammals but absent in rodents, where the ARF protein is encoded by a different exon structure. The ankyrin repeat domain of p16INK4a is highly conserved from Xenopus to humans, underscoring its critical role in CDK binding. The p14ARF protein, by contrast, shows poor primary sequence conservation but retains a conserved nucleolar localization signal and a conserved MDM2-binding motif in the N-terminal 37 amino acids.

---

## 2. 3D Protein Domain Architecture & Structural Biology

### 2.1 p16INK4a: The Ankyrin Repeat Fold

The p16INK4a protein is a **156-amino-acid polypeptide** with a molecular weight of approximately 16 kDa. Its structure, solved by NMR (PDB: 1BI7) and X-ray crystallography (PDB: 2A5E), consists of **four tandem ankyrin repeats** arranged in a linear array. Each ankyrin repeat is a 33-amino-acid motif comprising two antiparallel α-helices connected by a β-hairpin loop. The repeats stack to form an elongated, L-shaped structure with a concave surface that mediates protein–protein interactions.

**Domain boundaries (p16INK4a):**
- **Ankyrin Repeat 1:** Residues 15–47
- **Ankyrin Repeat 2:** Residues 48–80
- **Ankyrin Repeat 3:** Residues 81–113
- **Ankyrin Repeat 4:** Residues 114–146
- **N-terminal flexible region:** Residues 1–14 (disordered in solution)
- **C-terminal tail:** Residues 147–156 (contributes to CDK4 binding)

The **concave surface** formed by the inner helices of the ankyrin repeats contains the CDK4/6 binding interface. Key residues involved in CDK4 binding include **Asp84**, **His98**, and **Asp108**—mutations at these positions abolish inhibitory activity. The **convex surface** is solvent-exposed and may mediate interactions with other proteins, including the transcriptional co-repressor **HDAC1**.

### 2.2 p14ARF: An Intrinsically Disordered Protein

p14ARF (132 amino acids, ~14 kDa) is largely **intrinsically disordered** in solution, a feature that allows it to engage multiple binding partners through induced-fit mechanisms. Despite the lack of a stable tertiary structure, p14ARF contains several functionally critical regions:

- **N-terminal MDM2-binding domain (residues 1–37):** This region is necessary and sufficient for MDM2 binding and p53 stabilization. It contains a conserved **RxxL** motif (residues 21–24) that mimics a substrate-binding sequence.
- **Nucleolar localization signal (NoLS):** Residues 82–101, rich in arginine and lysine residues, directs p14ARF to the nucleolus.
- **C-terminal domain (residues 102–132):** Involved in self-oligomerization and interaction with the [ribosomal RNA](/knowledge/bioinformatics/ribosomal-rna-structure-taxonomic-profiling) processing factor **NPM1 (B23)**.

The absence of a defined globular fold means that p14ARF is not amenable to traditional X-ray crystallography; its structure has been studied primarily by NMR and small-angle X-ray scattering (SAXS), revealing an ensemble of extended conformations.

### 2.3 Structural Basis of CDK4/6 Inhibition

The binding of p16INK4a to CDK4/6 induces a conformational change in the kinase that allosterically inhibits ATP binding. The p16INK4a–CDK6 complex structure (PDB: 1BI7) reveals that p16INK4a binds to the **N-terminal lobe** of CDK6, causing a rotation of the C-helix that misaligns the ATP-binding site. This mechanism is distinct from that of the CIP/KIP family inhibitors (p21, p27), which bind to the cyclin–CDK interface. The binding affinity of p16INK4a for CDK6 is in the low nanomolar range (Kd ≈ 10 nM), whereas its affinity for CDK4 is slightly lower (Kd ≈ 50 nM).

### 2.4 Interactive 3D Visualizer

[Interactive 3D Protein Visualizer: Load CDKN2A (PDB: 1BI7)](/tools/protein-structure-viewer?source=direct&pdbId=1BI7)

The visualizer tool allows users to rotate the NMR structure of p16INK4a, highlight the four ankyrin repeats, and map clinically relevant missense mutations onto the 3D fold. Users can toggle between cartoon, surface, and electrostatic representations to examine the CDK4/6 binding interface.

---

## 3. Cellular Signaling Pathways & Molecular Function

### 3.1 The RB1–E2F Axis: G1/S Checkpoint Control

The primary function of p16INK4a is to enforce the **G1/S cell cycle checkpoint**. In cycling cells, the retinoblastoma protein (RB1) is phosphorylated by CDK4/6–cyclin D complexes, leading to the release of E2F transcription factors and the expression of S-phase genes. p16INK4a binds to CDK4/6 and prevents their association with D-type cyclins, thereby maintaining RB1 in its hypophosphorylated, growth-suppressive state.

The pathway operates as a **rheostat**: low levels of p16INK4a permit cell cycle progression, while high levels—induced by senescence signals—cause irreversible G1 arrest. The p16INK4a–RB1 pathway is functionally redundant with the p53 pathway in some contexts, but p16INK4a is uniquely required for **cellular senescence** in response to telomere shortening and oxidative stress.

### 3.2 The ARF–MDM2–p53 Axis

p14ARF functions as a **sensor of oncogenic stress**. Under normal conditions, p53 is maintained at low levels through MDM2-mediated ubiquitination and proteasomal degradation. When oncogenes such as Myc, Ras, or E2F1 are hyperactivated, p14ARF transcription is induced. The p14ARF protein then translocates to the nucleolus and binds MDM2, sequestering it and preventing p53 ubiquitination. This leads to p53 stabilization and the transcriptional activation of p53 target genes, including p21CIP1, BAX, and PUMA, culminating in cell cycle arrest or apoptosis.

The interaction between p14ARF and MDM2 is mediated by the N-terminal domain of p14ARF and the **N-terminal p53-binding pocket** of MDM2. p14ARF also promotes MDM2 degradation by relocalizing it to the nucleolus and by inhibiting MDM2's E3 ligase activity. Additionally, p14ARF can interact with **MDMX (MDM4)**, a homolog of MDM2, further enhancing p53 stability.

### 3.3 Cross-Talk Between the Two Pathways

Although p16INK4a and p14ARF are encoded by the same locus, their pathways are interconnected at multiple levels:

- **Shared upstream regulators:** Both promoters are repressed by PRC2 and activated by ETS transcription factors.
- **Functional redundancy:** Loss of both proteins (via homozygous deletion of CDKN2A) disables both the RB1 and p53 tumor suppressor pathways, a combination that strongly promotes tumorigenesis.
- **Feedback regulation:** p53 activation induces p21CIP1, which inhibits CDK2 but not CDK4/6, allowing p16INK4a to remain the dominant CDK4/6 inhibitor in senescent cells.

### 3.4 Protein–Protein Interaction Network

BioGRID and STRING databases list over 50 high-confidence interaction partners for p16INK4a and p14ARF. Key interactions include:

- **p16INK4a:** CDK4, CDK6, cyclin D1, HDAC1, and the transcriptional regulator **E2F1**.
- **p14ARF:** MDM2, MDMX, NPM1, Myc, and the ribosomal protein **RPL11** (which links ARF to ribosome biogenesis).

The interaction of p14ARF with NPM1 is particularly notable: p14ARF inhibits NPM1's ribonuclease activity, thereby suppressing rRNA processing and ribosome assembly. This function is independent of p53 and contributes to ARF's tumor suppressor activity.

### 3.5 Mermaid Diagram: Integrated Signaling Pathway

```mermaid
flowchart TD
    A["Oncogenic Stress: Myc, Ras, E2F1"] --> B["p14ARF Induction"]
    B --> C["p14ARF binds MDM2"]
    C --> D["MDM2 sequestration in nucleolus"]
    D --> E["p53 Stabilization"]
    E --> F["p21CIP1, BAX, PUMA transcription"]
    F --> G["Cell Cycle Arrest / Apoptosis"]

    H["Cyclin D1 + CDK4/6"] --> I["RB1 Phosphorylation"]
    I --> J["E2F Release"]
    J --> K["S-phase Gene Expression"]
    L["p16INK4a"] --> M["Inhibits CDK4/6"]
    M --> N["Hypophosphorylated RB1"]
    N --> O["E2F Sequestration"]
    O --> P["G1 Arrest"]

    G --> Q["Senescence"]
    P --> Q
```

---

## 4. Pathogenic Hotspot Mutations & Clinical Differentials

### 4.1 Germline Mutations in Familial Melanoma

Germline mutations in CDKN2A are the most common known genetic cause of **familial atypical multiple mole melanoma (FAMMM)** syndrome, accounting for 20–40% of families with high-penetrance melanoma susceptibility. The lifetime risk of melanoma in carriers is 50–80%, and carriers also have a 15–20% lifetime risk of pancreatic adenocarcinoma.

**Recurrent missense mutations in p16INK4a:**

| **Mutation** | **Domain** | **Functional Consequence** | **ClinVar Classification** |
|---|---|---|---|
| p.R24P | Ankyrin Repeat 1 | Disrupts CDK4 binding | Pathogenic |
| p.A57V | Ankyrin Repeat 2 | Reduces protein stability | Pathogenic |
| p.H98Y | Ankyrin Repeat 3 | Abolishes CDK6 binding | Pathogenic |
| p.D108N | Ankyrin Repeat 4 | Disrupts ankyrin fold | Pathogenic |
| p.P114S | Ankyrin Repeat 4 | Alters CDK4/6 specificity | Likely pathogenic |

**Mutations affecting p14ARF specifically:** Because Exon 1β is unique to p14ARF, mutations in this exon (e.g., p.R22X, p.L32R) selectively impair the ARF–MDM2 axis without affecting p16INK4a. These mutations are rare but are associated with a similar melanoma risk, confirming the independent tumor suppressor activity of p14ARF.

**Dual-coding mutations in Exon 2:** A single nucleotide change in Exon 2 can affect both proteins. For example, the c.377T>A transversion results in p16INK4a p.V126D and p14ARF p.P94H. The clinical phenotype depends on the combined impact on both proteins.

### 4.2 Somatic Alterations in Sporadic Cancers

Somatic inactivation of CDKN2A occurs through three principal mechanisms:

1. **Homozygous deletion:** Most common in glioblastoma (50–70%), mesothelioma (40–50%), and acute lymphoblastic leukemia (30–40%). Deletions often extend to include CDKN2B and MTAP.
2. **Promoter hypermethylation:** Silences p16INK4a expression in colorectal, lung, and breast cancers. Methylation of the p14ARF promoter is less common.
3. **Intragenic mutations:** Nonsense and frameshift mutations are distributed throughout Exon 2, while missense mutations cluster in the ankyrin repeat domains.

### 4.3 Clinical Differential Diagnosis

The differential diagnosis for a patient with multiple atypical nevi and a family history of melanoma includes:

- **CDKN2A mutations:** Most common; associated with pancreatic cancer risk.
- **CDK4 mutations (p.R24C):** Rare; cause familial melanoma by preventing p16INK4a binding.
- **BAP1 mutations:** Cause a distinct syndrome with mesothelioma and uveal melanoma.
- **MITF mutations (p.E318K):** Low-penetrance melanoma susceptibility.
- **PTEN mutations:** Associated with Cowden syndrome and melanoma.

Genetic testing for CDKN2A is recommended in families with ≥3 affected members, multiple primary melanomas, or a history of pancreatic cancer.

---

## 5. Host-Pathogen & Viral Interactions

### 5.1 Human Papillomavirus (HPV) E7 Oncoprotein

The **HPV E7 protein** is a well-characterized viral oncoprotein that inactivates the RB1 pathway. E7 binds to RB1 and promotes its proteasomal degradation, thereby mimicking the effects of CDKN2A loss. However, HPV E7 also has direct effects on p16INK4a: E7 expression leads to a **paradoxical upregulation of p16INK4a** through a feedback loop involving E2F1. This phenomenon is exploited clinically: **p16INK4a immunohistochemistry** is used as a surrogate marker for HPV-driven oropharyngeal and cervical cancers. In these tumors, high p16INK4a expression indicates functional inactivation of RB1 by E7, not CDKN2A loss.

### 5.2 Simian Virus 40 (SV40) Large T Antigen

SV40 large T antigen binds to both RB1 and p53, inactivating both tumor suppressor pathways. The T antigen also interacts with p14ARF, promoting its degradation and thereby disabling the ARF–MDM2–p53 axis. This dual inactivation is essential for SV40-mediated cellular transformation.

### 5.3 Adenovirus E1A and E1B

Adenovirus E1A binds RB1 and displaces E2F, while E1B-55K binds p53 and promotes its degradation. The combined action of E1A and E1B phenocopies the loss of both CDKN2A products. Notably, E1A also induces p14ARF expression, but E1B-55K counteracts this by degrading p53.

### 5.4 Kaposi's Sarcoma-Associated Herpesvirus (KSHV)

KSHV encodes the viral cyclin **v-cyclin**, which binds CDK6 and is resistant to inhibition by p16INK4a. This allows KSHV-infected cells to bypass the G1/S checkpoint despite high levels of p16INK4a. The v-cyclin–CDK6 complex also phosphorylates RB1 and other substrates, promoting viral replication.

---

## 6. [Pharmacogenomics](/knowledge/bioinformatics/pharmacogenomics-tailoring-drugs-to-genetic-profiles), Drug Targets & Small-Molecule Inhibitors

### 6.1 CDK4/6 Inhibitors: Exploiting p16INK4a Loss

The loss of p16INK4a in cancer cells creates a dependency on CDK4/6 activity. This dependency is the basis for the therapeutic use of **CDK4/6 inhibitors** in cancers with CDKN2A loss or RB1 retention.

**FDA-approved CDK4/6 inhibitors:**

| **Drug** | **Target** | **Approved Indications** | **Mechanism** |
|---|---|---|---|
| Palbociclib (Ibrance) | CDK4/6 | HR+/HER2− breast cancer | ATP-competitive inhibitor |
| Ribociclib (Kisqali) | CDK4/6 | HR+/HER2− breast cancer | ATP-competitive inhibitor |
| Abemaciclib (Verzenio) | CDK4/6 | HR+/HER2− breast cancer | ATP-competitive inhibitor; also inhibits CDK9 |

These drugs are most effective in tumors with **RB1 wild-type** status, as RB1 loss confers resistance. Biomarker studies are evaluating whether CDKN2A loss predicts response to CDK4/6 inhibitors in other tumor types, including liposarcoma and glioblastoma.

### 6.2 Reactivation of p16INK4a Expression

Several strategies aim to restore p16INK4a expression in tumors where it is silenced by promoter methylation:

- **DNA methyltransferase inhibitors (DNMTis):** 5-azacitidine and decitabine can demethylate the CDKN2A promoter and restore p16INK4a expression. These drugs are approved for myelodysplastic syndromes and are being tested in solid tumors.
- **Histone deacetylase inhibitors (HDACis):** Vorinostat and romidepsin increase p16INK4a expression by altering chromatin structure. They are approved for cutaneous T-cell lymphoma.
- **Combination therapy:** DNMTis and HDACis are often combined to synergistically reactivate silenced tumor suppressors.

### 6.3 MDM2 Inhibitors: Targeting the ARF–MDM2 Axis

In tumors that retain wild-type p53 but have lost p14ARF, **MDM2 inhibitors** can reactivate p53 by blocking the MDM2–p53 interaction.

**Investigational MDM2 inhibitors:**

| **Drug** | **Target** | **Phase** | **Notes** |
|---|---|---|---|
| Nutlin-3a | MDM2 | Preclinical | First-in-class cis-imidazoline analog |
| Idasanutlin (RG7388) | MDM2 | Phase III | Improved potency and oral bioavailability |
| APG-115 | MDM2 | Phase II | Active in salivary gland carcinoma |
| KRT-232 | MDM2 | Phase II | Being tested in AML and Merkel cell carcinoma |

These agents are most effective in tumors with wild-type p53 and are being combined with chemotherapy and immunotherapy.

### 6.4 Gene Therapy and Synthetic Lethality

- **Oncolytic viruses:** Modified adenoviruses (e.g., ONYX-015) that replicate selectively in p53-deficient cells are being tested in tumors with CDKN2A loss.
- **Synthetic lethality:** Tumors with homozygous CDKN2A deletion often co-delete MTAP, creating a vulnerability to **PRMT5 inhibitors**. MTAP loss leads to accumulation of methylthioadenosine, which inhibits PRMT5; further PRMT5 inhibition is synthetically lethal. Several PRMT5 inhibitors are in early-phase trials.

---

## 7. Bioinformatic Resources & Database Accessions

| **Database** | **Accession/ID** | **URL** |
|---|---|---|
| NCBI Gene | 1029 | https://www.ncbi.nlm.nih.gov/gene/1029 |
| Ensembl | ENSG00000147889 | https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000147889 |
| UniProt (p16INK4a) | P42771 | https://www.uniprot.org/uniprotkb/P42771 |
| UniProt (p14ARF) | Q8N726 | https://www.uniprot.org/uniprotkb/Q8N726 |
| RCSB PDB | 1BI7 | https://www.rcsb.org/structure/1BI7 |
| ClinVar | Gene: CDKN2A | https://www.ncbi.nlm.nih.gov/clinvar/?term=CDKN2A |
| COSMIC | CDKN2A | https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=CDKN2A |
| Gene Ontology (GO) | GO:0004860 (protein kinase inhibitor activity); GO:0005515 (protein binding) | https://www.ebi.ac.uk/QuickGO/ |
| STRING | CDKN2A (P42771) | https://string-db.org/network/P42771 |
| BioGRID | CDKN2A | https://thebiogrid.org/107309 |
| gnomAD | CDKN2A | https://gnomad.broadinstitute.org/gene/ENSG00000147889 |
| cBioPortal | CDKN2A | https://www.cbioportal.org/ |

---

## Related Clinical & Scientific Guides

* [PIK3CA (PI3K Alpha): Helical and Kinase Domain Hotspot Mutations and Isoform-Specific Inhibition](/knowledge/bioinformatics/genes/cancer-genomics/pik3ca-gene-structure-function-pathway)
* [ENTPD5 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/cancer-genomics/entpd5-gene-structure-function-pathway)
* [PDGFB Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/cancer-genomics/pdgfb-gene-structure-function-pathway)


## References

1. Serrano M, Hannon GJ, Beach D. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. *Nature*. 1993;366(6456):704-707. doi:10.1038/366704a0. https://www.nature.com/articles/366704a0
2. Quelle DE, Zindy F, Ashmun RA, Sherr CJ. Alternative reading frames of the INK4a tumor suppressor gene encode two unrelated proteins capable of inducing cell cycle arrest. *Cell*. 1995;83(6):993-1000. doi:10.1016/0092-8674(95)90214-7. https://www.cell.com/cell/abstract/S0092-8674(95)90214-7
3. Kamb A, Gruis NA, Weaver-Feldhaus J, et al. A cell cycle regulator potentially involved in genesis of many tumor types. *Science*. 1994;264(5157):436-440. doi:10.1126/science.8153634. https://www.science.org/doi/10.1126/science.8153634
4. Zhang Y, Xiong Y, Yarbrough WG. ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways. *Cell*. 1998;92(6):725-734. doi:10.1016/S0092-8674(00)81401-4. https://www.cell.com/cell/abstract/S0092-8674(00)81401-4
5. Pomerantz J, Schreiber-Agus N, Liégeois NJ, et al. The Ink4a tumor suppressor gene product, p19Arf, interacts with MDM2 and neutralizes MDM2's inhibition of p53. *Cell*. 1998;92(6):713-723. doi:10.1016/S0092-8674(00)81400-2. https://www.cell.com/cell/abstract/S0092-8674(00)81400-2
6. Byeon IJ, Li J, Ericson K, et al. Tumor suppressor p16INK4A: determination of solution structure and p4CDK4 complex formation. *Mol Cell*. 1998;1(3):421-431. doi:10.1016/S1097-2765(00)80042-8. https://www.cell.com/molecular-cell/abstract/S1097-2765(00)80042-8
7. Ruas M, Peters G. The p16INK4a/CDKN2A tumor suppressor and its relatives. *Biochim Biophys Acta*. 1998;1378(2):F115-F177. doi:10.1016/S0304-419X(98)00017-1. https://www.sciencedirect.com/science/article/pii/S0304419X98000171
8. Sharpless NE, DePinho RA. The INK4A/ARF locus and its two gene products. *Curr Opin Genet Dev*. 1999;9(1):22-30. doi:10.1016/S0959-437X(99)80004-5. https://www.sciencedirect.com/science/article/pii/S0959437X99800045
9. Sherr CJ. The INK4a/ARF network in tumour suppression. *Nat Rev Mol Cell Biol*. 2001;2(10):731-737. doi:10.1038/35096061. https://www.nature.com/articles/35096061
10. Goldstein AM, Chan M, Harland M, et al. High-risk melanoma susceptibility genes and pancreatic cancer, neural system tumors, and uveal melanoma across GenoMEL. *Cancer Res*. 2006;66(20):9818-9828. doi:10.1158/0008-5472.CAN-06-0494. https://cancerres.aacrjournals.org/content/66/20/9818
11. Sharpless NE, Bardeesy N, Lee KH, et al. Loss of p16Ink4a with retention of p19Arf predisposes mice to tumorigenesis. *Nature*. 2001;413(6851):86-91. doi:10.1038/35092592. https://www.nature.com/articles/35092592
12. Kim WY, Sharpless NE. The regulation of INK4/ARF in cancer and aging. *Cell*. 2006;127(2):265-275. doi:10.1016/j.cell.2006.10.003. https://www.cell.com/cell/abstract/S0092-8674(06)01305-1
13. Mistry SH, Taylor C, Randerson-Moor JA, et al. Prevalence of 9p21 deletions in UK melanoma families. *Genes Chromosomes Cancer*. 2005;44(3):292-300. doi:10.1002/gcc.20241. https://onlinelibrary.wiley.com/doi/10.1002/gcc.20241
14. Krimpenfort P, Quon KC, Mooi WJ, Loonstra A, Berns A. Loss of p16Ink4a confers susceptibility to metastatic melanoma in mice. *Nature*. 2001;413(6851):83-86. doi:10.1038/35092584. https://www.nature.com/articles/35092584
15. Serrano M, Lee H, Chin L, Cordon-Cardo C, Beach D, DePinho RA. Role of the INK4a locus in tumor suppression and cell mortality. *Cell*. 1996;85(1):27-37. doi:10.1016/S0092-8674(00)81079-X. https://www.cell.com/cell/abstract/S0092-8674(00)81079-X
16. Weber JD, Taylor LJ, Roussel MF, Sherr CJ, Bar-Sagi D. Nucleolar Arf sequesters Mdm2 and activates p53. *Nat Cell Biol*. 1999;1(1):20-26. doi:10.1038/8991. https://www.nature.com/articles/ncb0599_020
17. Loughran O, Malliri A, Owens D, et al. Association of CDKN2A/p16INK4A with human head and neck keratinocyte replicative senescence: relationship of dysfunction to immortality and neoplasia. *Oncogene*. 1996;13(3):561-568. https://pubmed.ncbi.nlm.nih.gov/8760299/
18. Huschtscha LI, Noble JR, Neumann AA, et al. Loss of p16INK4 expression by methylation is associated with lifespan extension of human mammary epithelial cells. *Cancer Res*. 1998;58(16):3508-3512. https://cancerres.aacrjournals.org/content/58/16/3508
19. Rocco JW, Sidransky D. p16(MTS-1/CDKN2/INK4a) in cancer progression. *Exp Cell Res*. 2001;264(1):42-55. doi:10.1006/excr.2000.5149. https://www.sciencedirect.com/science/article/pii/S0014482700951494
20. Foulkes WD, Flanders TY, Pollock PM, Hayward NK. The CDKN2A (p16) gene and human cancer. *Mol Med Today*. 1997;3(3):102-107. doi:10.1016/S1357-4310(96)10055-X. https://www.sciencedirect.com/science/article/pii/S135743109610055X
21. Ruas M, Brookes S, McDonald NQ, Peters G. Functional evaluation of tumour-specific variants of p16INK4a/CDKN2A: correlation with [protein structure](/knowledge/bioinformatics/protein-structure-biophysical-levels-folding) information. *Oncogene*. 1999;18(39):5423-5434. doi:10.1038/sj.onc.1202921. https://www.nature.com/articles/1202921
22. Orlow I, LaRue H, Osman I, et al. Deletions of the INK4A gene in superficial bladder tumors. *Am J Pathol*. 1999;155(1):105-113. doi:10.1016/S0002-9440(10)65104-6. https://www.sciencedirect.com/science/article/pii/S0002944010651046
23. Esteller M, Tortola S, Toyota M, et al. Hypermethylation-associated inactivation of p14(ARF) is independent of p16(INK4a) methylation and p53 mutational status. *Cancer Res*. 2000;60(1):129-133. https://cancerres.aacrjournals.org/content/60/1/129
24. Gonzalgo ML, Bender CM, You EH, et al. Low frequency of p16/CDKN2A methylation in sporadic melanoma: comparative approaches for methylation analysis of primary tumors. *Cancer Res*. 1997;57(23):5336-5347. https://cancerres.aacrjournals.org/content/57/23/5336
25. Larsen CJ. p16INK4a: a gene with a dual capacity to encode unrelated proteins that inhibit cell cycle progression. *Oncogene*. 1996;12(10):2041-2044. https://pubmed.ncbi.nlm.nih.gov/8668346/
26. Quelle DE, Cheng M, Ashmun RA, Sherr CJ. Cancer-associated mutations at the INK4a locus cancel cell cycle arrest by p16INK4a but not by the alternative reading frame protein p19ARF. *Proc Natl Acad Sci USA*. 1997;94(2):669-673. doi:10.1073/pnas.94.2.669. https://www.pnas.org/